Smart probe could help surgeons remove all cancer in one go

NCT ID NCT05104619

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a device called SpiderMass that analyzes tissue molecules in real time during tongue cancer surgery. The goal is to help surgeons instantly tell cancerous from healthy tissue, so they can remove all the tumor in one operation. Currently, about 15-30% of patients need additional treatment because cancer cells are found at the surgical edge days later. This trial enrolls 33 adults with squamous cell carcinoma of the tongue who are having surgery as their first treatment. The device is being trained to recognize cancer patterns, which is the first step toward using it as a surgical guide.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

SpiderMass spectroscopy probe

What this could lead to

If successful, this technology could help surgeons remove all cancer during one operation, reducing the need for follow-up treatments.

What could go wrong

This is an early learning phase with only 33 participants. The technology must first be trained to distinguish healthy from cancerous tissue, and it may not work in all cases.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SQUAMOUS CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Margins of Excision squamous cell carcinoma tongue disorder tongue squamous cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Centre Hospitalier Universitaire d'Amiens

    RECRUITING

    Amiens, Picardie, 80000, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••